1
|
Bourget P, Amin A, Chandesris MO, Vidal F, Merlette C, Hirsch I, Cabaret L, Carvalhosa A, Mogenet A, Frenzel L, Damaj G, Lortholary O, Hermine O. Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis. J Chromatogr B Analyt Technol Biomed Life Sci 2013; 944:175-81. [PMID: 24316764 DOI: 10.1016/j.jchromb.2013.11.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2013] [Revised: 10/28/2013] [Accepted: 11/01/2013] [Indexed: 01/16/2023]
Abstract
We developed and validated quantitative bioanalytical liquid chromatography-tandem mass spectrometry assay for the protein kinase inhibitor, midostaurin. Plasma samples were pre-treated using a protein precipitation with methanol containing midostaurin-d5 as an internal standard. After centrifugation, 5μL of the supernatant was injected into the chromatographic system. The system consisted of a 3.5μm particle bonded octadecyl silica column, with gradient elution using a mixture of 0.1% (v/v) formic acid in acetonitrile and 10mM ammonium formate in water with 0.1% formic acid. The analyte was quantified using the selected reaction-monitoring mode of a triple quadrupole mass spectrometer equipped with a heated electrospray interface. The assay was validated in a 75-2500ng/mL calibration range. For quality control, within-day and between-day precisions were 1.2-2.8%, and 1.2-6.9%, respectively. The β-expectation tolerance limit (accuracy) met the limits of acceptance ±15% (±20% for the LLQ). The drug was sufficiently stable under all relevant analytical conditions. The assay has successfully been used to assess drug levels for therapeutic drug monitoring in patients presenting advanced systemic mastocytosis and treated with the promising midostaurin.
Collapse
Affiliation(s)
- Philippe Bourget
- Clinical Pharmacy, Necker Hospital, 149 rue de Sèvres, Paris 75015, France.
| | - Alexandre Amin
- Clinical Pharmacy, Necker Hospital, 149 rue de Sèvres, Paris 75015, France.
| | - Marie-Olivia Chandesris
- Hematology Department, Necker Hospital, 149 rue de Sèvres, Paris 75015, France; Centre de référence des mastocytoses (CEREMAST), Necker Hospital, 149 rue de Sèvres, Paris 75015, France
| | - Fabrice Vidal
- Clinical Pharmacy, Necker Hospital, 149 rue de Sèvres, Paris 75015, France
| | | | - Isabelle Hirsch
- Centre de référence des mastocytoses (CEREMAST), Necker Hospital, 149 rue de Sèvres, Paris 75015, France
| | - Laure Cabaret
- Centre de référence des mastocytoses (CEREMAST), Necker Hospital, 149 rue de Sèvres, Paris 75015, France
| | - Ana Carvalhosa
- Hematology Department, Necker Hospital, 149 rue de Sèvres, Paris 75015, France
| | - Agnès Mogenet
- Clinical Investigation Department (CIC), Necker Hospital, 149 rue de Sèvres, Paris 75015, France
| | - Laurent Frenzel
- Hematology Department, Necker Hospital, 149 rue de Sèvres, Paris 75015, France
| | - Gandhi Damaj
- Centre de référence des mastocytoses (CEREMAST), Necker Hospital, 149 rue de Sèvres, Paris 75015, France; Hematology Department, Amiens University Hospital, Place Victor Pauchet, Amiens 80054, France
| | - Olivier Lortholary
- Centre de référence des mastocytoses (CEREMAST), Necker Hospital, 149 rue de Sèvres, Paris 75015, France; Infectious Diseases Department (SMIT), Necker Hospital, 149 rue de Sèvres, Paris 75015, France
| | - Olivier Hermine
- Hematology Department, Necker Hospital, 149 rue de Sèvres, Paris 75015, France; Centre de référence des mastocytoses (CEREMAST), Necker Hospital, 149 rue de Sèvres, Paris 75015, France; CNRS UMR 8147, University Paris V, 15 rue de l'école de médecine, Paris 75006, France
| |
Collapse
|